arsenic trioxide

(redirected from Trisenox)
Also found in: Thesaurus, Medical, Encyclopedia.

ar·se·nic trioxide

 (är′sə-nĭk)
n.
A poisonous, white amorphous powder, As2O3, used in insecticides, rat poisons, weed killers, pigments, and preservatives for hides and wood.

arsenic trioxide

n
(Elements & Compounds) a white poisonous powder used in the manufacture of glass and as an insecticide, rat poison, and weedkiller. Formula: As2O3. Also called: arsenic

ar′senic triox′ide


n.
a white, tasteless, poisonous powder, As2O3, used chiefly in the manufacture of pigments and glass and as an insecticide or weed-killer.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.arsenic trioxide - a white powdered poisonous trioxide of arsenicarsenic trioxide - a white powdered poisonous trioxide of arsenic; used in manufacturing glass and as a pesticide (rat poison) and weed killer
trioxide - an oxide containing three atoms of oxygen in the molecule
References in periodicals archive ?
M2 PHARMA-January 23, 2018-Teva to Pay CTI BioPharma USD 10m Milestone Payment with FDA Approval of Trisenox for Acute Promyelocytic Leukemia
M2 EQUITYBITES-January 18, 2018-CTI BioPharma anticipates USD10m in milestone payment for TRISENOX in February 2018
He has successfully led and managed the late development and approval of several anticancer drugs, including Halaven, Trisenox and Xyotax.
BANKING AND CREDIT NEWS-December 5, 2014-CTI BioPharma gets USD15m milestone payment for TRISENOX
The company's proprietary products in the United States include: AMRIX (cyclobenzaprine hydrochloride extended-release capsules), TREANDA (bendamustine hydrochloride) for Injection, FENTORA (fentanyl buccal tablet) (C-II), PROVIGIL (modafinil) Tablets (C-IV), TRISENOX (arsenic trioxide) injection, GABITRIL (tiagabine hydrochloride), NUVIGIL (armodafinil) Tablets (C-IV) and ACTIQ (oral transmucosal fentanyl citrate) (C-II).
The company's proprietary products in the United States include: PROVIGIL(r) (modafinil) Tablets [C-IV], FENTORA(r) (fentanyl buccal tablet) [C-II], TRISENOX injection, TREANDA, AMRIX(r) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(r) (naltrexone for extended-release injectable suspension), GABITRIL(r) (tiagabine hydrochloride), NUVIGIL(tm) (armodafinil) Tablets [C-IV] and ACTIQ(r) (oral transmucosal fentanyl citrate) [C-II].
Food and Drug Administration (FDA) approved the drug Trisenox (arsenic trioxide; Cell Therapeutics, Inc.
SYNRIBO joins TREANDA and TRISENOX as important hematologic treatment options in the Teva Oncology portfolio.
M2 PHARMA-January 18, 2018-CTI BioPharma anticipates USD10m in milestone payment for TRISENOX in February 2018
M2 EQUITYBITES-June 15, 2017-CTI BioPharma accepts USD10m milestone payment for TRISENOX
I am very proud of these accomplishments, including, TRISENOX (arsenic trioxide) now the standard of care in treating patients with a rare form of leukemia; expanding the indication for ZEVALIN (ibritumomab tiuxetan), the first approved radio-immunotherapy for patients with a chronic form of lymphoma; and PIXUVRI (pixantrone), the first and only treatment approved for patients with relapsed aggressive B-cell non-Hodgkin lymphoma.
M2 EQUITYBITES-December 14, 2015-CTI BioPharma wins USD10m milestone payment for TRISENOX from Teva Pharmaceutical